Non-OR13A1 mRNAs with partial complementarity

Non-OR13A1 mRNAs with partial complementarity refers to a collection of messenger RNA (mRNA) transcripts that are not the intended therapeutic target, Olfactory Receptor Family 13 Subfamily A Member 1 (OR13A1), but possess sequences that are partially complementary to drugs designed to target OR13A1. This term is primarily used in the context of RNA-based therapeutics, such as small interfering RNAs (siRNAs), small activating RNAs (saRNAs), or antisense oligonucleotides (ASOs), where the specificity of the drug is determined by base-pairing (Jackson et al., 2003). When a drug designed for OR13A1 binds to these non-target mRNAs, it can trigger unintended gene silencing or translational repression, a phenomenon known as off-target activity (Birmingham et al., 2006). While OR13A1 itself is being investigated as a potential therapeutic target and biomarker in diseases such as glioma and prostate cancer due to its ectopic expression in these tissues, the non-OR13A1 transcripts represent a significant safety concern (Flegel et al., 2016). Unintended interactions with these mRNAs can lead to cellular toxicity, loss of essential protein functions, and adverse clinical side effects. Consequently, this entity is not a therapeutic target but a classification of off-target risks that must be minimized during the drug development process to ensure high specificity and safety.

Other names

OR13A1 off-target transcriptsNon-target mRNAs with sequence homology to OR13A1Off-target mRNAs of OR13A1-targeting agents

Unintended binding of RNA-targeted therapeutics to transcripts with partial sequence complementarity, leading to mRNA degradation or translational inhibition.